Evidence map›Paper›PMID 27038444›Full record

ArticleJournal of gastrointestinal cancer2016

Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients.

Faruk Tas, Elif Bilgin, Didem Tastekin, Kayhan Erturk, Derya Duranyildiz

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Faruk TasInstitute of Oncology, University of Istanbul, 34390, Istanbul, Turkey. faruktas2002@yahoo.com.
Elif BilginInstitute of Oncology, University of Istanbul, 34390, Istanbul, Turkey.
Didem TastekinInstitute of Oncology, University of Istanbul, 34390, Istanbul, Turkey.
Kayhan ErturkInstitute of Oncology, University of Istanbul, 34390, Istanbul, Turkey.
Derya DuranyildizInstitute of Oncology, University of Istanbul, 34390, Istanbul, Turkey.
Istanbul University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGalectin-3, a member of the galectin family, is an endogenous β-galactoside-binding lectin. It plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of galectin-3 in gastric cancer patients. MATERIAL AND

methodsA total of 58 patients with diagnosis of gastric cancer were enrolled into this study. Serum galectin-3 concentrations were determined by the solid-phase sandwich ELISA method. Age- and sex-matched 30 healthy controls were included in the analysis.

resultsThe median age at diagnosis was 59.5 years, range 32 to 82 years. There was no significant difference in the baseline serum galectin-3 levels between gastric cancer patients and healthy controls (p = 0.357). The older patients had elevated galectin-3 levels compared with younger ones (p = 0.02). The other known clinical variables including gender, site of lesion, histopathology, tumor size, lymph node involvement, and stage of disease were not correlated with serum galectin-3 concentrations (p > 0.05). Moreover, no relationship was shown between serum galectin-3 level and chemotherapy responsiveness (p = 0.36). Likewise, serum galectin-3 concentrations were not associated with prognosis on survival (p = 0.54).

conclusionSerum levels of galectin-3 have no diagnostic, predictive and prognostic roles in gastric cancer patients.

Indexed as

AdultAgedAged, 80 and overFemaleGalectin 3HumansMaleMiddle AgedStomach NeoplasmsGalectin 3Galectin-3Gastric cancerSerum

Identifiers

PMID27038444
OpenAlexW2315562104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.